Novartis and Novo Nordisk heart drugs failed large trials weeks apart. Analysts say the results could cool investment in cardiovascular drug development.
Back to Back Heart Drug Failures at Novartis and Novo Nordisk Undercut Two Leading Theories of Cardiovascular Risk
by | Sep 14, 2026 | Uncategorized | 0 comments
Recent Comments